

Abstract of the Disclosure

The present invention is directed to antibodies which bind human gp39, are antagonistic of the CD40/CD40L interaction, but are non-agonistic of T-cell activation. The present invention is further directed to the use of these antibodies as
5 therapeutic agents. These antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.

0937441-060601
109090-1447860